Vaccinex, Inc. Stock

$0.75

2.74% day before yesterday

Nasdaq, Jun 30, 06:32 pm CET

ISIN

US9186401033

Symbol

VCNX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Vaccinex, Inc. Stock price

$0.75

-727.95 99.90% 5Y

Nasdaq, Closing price Tue, Jul 01 2025

+0.02 2.74%

ISIN

US9186401033

Symbol

VCNX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$2.0m

Enterprise Value

$930.0k

Net debt

positive

Cash

$1.1m

Shares outstanding

2.7m

Valuation (TTM | estimate)

P/E

negative | -

P/S

3.35 | -

EV/Sales

1.55 | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-95.84%

Return on Equity

748.95%

ROCE

755.44%

ROIC

758.50%

Debt/Equity

-0.01

Financials (TTM | estimate)

Revenue

$600.0k | -

EBITDA

$-18.6m | -

EBIT

$-18.7m

Net Income

$-18.6m | -

Free Cash Flow

$-16.2m

Growth (TTM | estimate)

Revenue

5.26% | -

EBITDA

18.14% | -

EBIT

18.13%

Net Income

8.00% | -

Free Cash Flow

6.30%

Margin (TTM | estimate)

Gross

EBITDA

-3,101.66% | -

EBIT

-3,117.30%

Net

-3,100.50% | -

Free Cash Flow

-2,696.84%

EPS

$-5.78

FCF per Share

$-6.05

Short interest

3.23%

Employees

25.00

Rev per Employee

$20.00k

As a Free StocksGuide user, you can view scores for all 6,952 stocks worldwide.

Get Started for Free Today

Vaccinex, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Vaccinex, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Vaccinex, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Vaccinex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.60 0.60	5% 5% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	6.79 6.79	1% 1% 1,132%
- Research and Development Expense	13 13	24% 24% 2,092%
EBITDA	-19 -19	18% 18% -3,107%
- Depreciation and Amortization	0.09 0.09	25% 25% 15%
EBIT (Operating Income) EBIT	-19 -19	18% 18% -3,123%
Net Profit	-19 -19	8% 8% -3,105%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Vaccinex, Inc. Stock News

Neutral

GlobeNewsWire

●

about one month ago

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.

Neutral

GlobeNewsWire

●

2 months ago

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer.

Neutral

GlobeNewsWire

●

4 months ago

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to d...

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Head office	United States
CEO	Maurice Zauderer
Employees	25
Founded	1997
Website	www.vaccinex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now